Ozempic vs. Mounjaro
See how Ozempic and Mounjaro compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Both are once-weekly injections, but Mounjaro activates GIP receptors in addition to GLP-1, a dual mechanism linked to greater average weight loss in trials.
Ozempic carries FDA approval for reducing cardiovascular events and slowing kidney disease in type 2 diabetics, uses Mounjaro's label does not currently include.
Neither drug is FDA-approved for weight loss on its own; that indication belongs to their sister products, Wegovy and Zepbound.
Ozempic vs. Mounjaro Drug Summary
Ozempic
Ozempic (semaglutide) is a GLP-1 receptor agonist approved to control blood sugar in adults with type 2 diabetes and to reduce cardiovascular and kidney risk in those with existing heart or kidney disease. It is given as a once-weekly subcutaneous injection with a gradual dose increase. Some clinicians prescribe it off-label for weight loss.
Mounjaro
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved to control blood sugar in adults and children 10 and older with type 2 diabetes. It is also given as a once-weekly subcutaneous injection with a longer, more gradual titration schedule. It is sometimes prescribed off-label for weight loss, and its sister drug Zepbound carries formal weight-loss approval.
Ozempic vs. Mounjaro Side Effects
Ozempic
Mounjaro
Ozempic vs. Mounjaro Dosage
Ozempic
Mounjaro
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2 mg once weekly | If needed |
| Dose changes | 3 increases | Every 4 weeks |
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Ozempic
| STAGE | DOSE | WHEN |
| Starting dose | 0.25 mg once weekly | Weeks 1-4 |
| Maximum dose | 2 mg once weekly | If needed |
| Dose changes | 3 increases | Every 4 weeks |
Mounjaro
| STAGE | DOSE | WHEN |
| Starting dose | 2.5 mg once weekly | Weeks 1-4 |
| Maximum dose | 15 mg once weekly | Week 21 onward |
| Dose changes | 5 increases | Every 4 weeks |
Ozempic vs. Mounjaro Indications
Ozempic
Ozempic is FDA-approved to manage blood sugar in adults with type 2 diabetes alongside diet and exercise. It also carries approval to lower the risk of heart attack, stroke, and cardiovascular death in diabetics with known heart disease, and to slow kidney damage in diabetics with chronic kidney disease.
Blood sugar control in type 2 diabetes (with diet and exercise)
Reduces cardiovascular risk in diabetics with heart disease
Slows chronic kidney disease progression in diabetics
Off-label: weight loss in people without diabetes
Mounjaro
Mounjaro is FDA-approved to manage blood sugar in adults with type 2 diabetes, and also in children 10 and older with the condition. It does not currently carry approval for cardiovascular or kidney protection.
Blood sugar control in adults with type 2 diabetes
Blood sugar control in children 10 and older with type 2 diabetes
Off-label: weight loss in people without diabetes
Related drug Zepbound is approved for weight loss and sleep apnea
Ozempic vs. Mounjaro Pros and Cons
Ozempic
Ozempic has the longer track record of the two, having been on the market since 2017, and its label includes protective effects on the heart and kidneys that Mounjaro's does not. It generally carries a lower list price, though both drugs share similar GI side effects and neither is approved specifically for weight loss.
Pros
FDA-approved to reduce cardiovascular events in diabetics with heart disease
FDA-approved to slow chronic kidney disease progression
Longer real-world track record, approved since 2017
Cons
Not FDA-approved for weight loss on its own
Single-mechanism GLP-1 agonist, may produce less weight loss than dual agonists
Requires separate prescription (Wegovy) if weight loss is the primary goal
Mounjaro
Mounjaro's dual GIP/GLP-1 mechanism has been associated with greater average weight loss in trials compared to GLP-1-only drugs. It is a newer medication with a longer titration schedule, and it does not carry Ozempic's cardiovascular or kidney protection claims.
Pros
Dual GIP/GLP-1 mechanism linked to greater average weight loss in trials
Approved for pediatric use (age 10+) in type 2 diabetes
Sister drug Zepbound carries formal FDA weight-loss approval
Cons
Roughly $1,000 to $1,300 per month without insurance, before savings programs
Not approved for cardiovascular or kidney risk reduction
Newer drug (approved 2022) with a shorter track record
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.